Comparing the effect of only bolus Eptifibatide with bolus plus infusion form of Eptifibatide on bleeding complications and consequences on myocardial infarct patients

Comparing the effect of receiving only bolus dose Eptifibatide with bolus plus infusion strategy on bleeding complications and consequences after Percutaneous Coronary Intervention (PCI) on Myocardial Infarct (MI) patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017071935183N1

Enrollment

176

Registered

2017-08-07

Start date

2017-07-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myocardial infarction. E1, E2, E3, E4, E9

Interventions

Intervention 1: the first group is received a bolus dose of 180 mcg/kg Eptifibatide (Integrilin company)from peripheral vein during 8 minutes, immediately before PCI and after that PCI is done.After P

Treatment - Drugs

the first group is received a bolus dose of 180 mcg/kg Eptifibatide (Integrilin company)from peripheral vein during 8 minutes, immediately before PCI and after that PCI is done.After PCI. all patients

Patients in the second group received routine treatment in addition with 10-hours infusion of 2 mcg/kg/min Eptifibatide with maximum dose of 15 mcg/hour and if patients creatinine clearance4, they wer

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria were as followed: 1) age more than 18 years, 2)having elevation in Troponin enzyme level, 3) having electrocardiogram changes due to infarction, 4)candidate for angioplasty and percutaneous coronary intervention, 5) having no contraindication for administrating Eptifibatide, 6) patient's willingness to participate in this study Exclusion criteria were as followed:1) Patient's unwillingness to continue his/ her participation, 2)history of stroke, 3)treating with anti coagulant medications, 4)using medications that has interaction with Eptifibatide, 5) have not experience PCI, 6)have experienced thrombectomy, 7) having sensitivity to Eptifibatide, 8) having uncontrolled hypertension, 9) dialysis patients

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Incidence of hematoma. Timepoint: immediately after intervention, 24, 48,72 and 96 hours after intervention. Method of measurement: observation.;Incidence of bleeding. Timepoint: immediately after intervention, 24, 48,72 and 96 hours after intervention. Method of measurement: observation.	—

Secondary

Measure	Time frame
Needs for additional coronary intervention. Timepoint: one week after intervention. Method of measurement: physical examination.;Death. Timepoint: one week after intervention. Method of measurement: observation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contacthasan shemirani

isfahan university of medical science

shemirani@med.mui.ac.ir+98 31 3260 0961

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026